跳至主要内容
临床试验/2023-508709-26-00
2023-508709-26-00招募中2 期

F-18 PSMA-11 PET for Imaging and Staging of Hepatocellular carcinoma with Evaluation of Survival

Universitair Ziekenhuis Gent1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2024年8月23日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
32
试验地点
1
主要终点
Per-lesion detection rate of F-18 PSMA-11 PET/CT, 60-90 minutes post-injection.

研究概览

简要总结

To determine the diagnostic accuracy of F-18 PSMA-11 PET/CT for the (re)staging of hepatocellular carcinoma (HCC) compared to F-18 FDG PET/CT and F-18 Choline PET/CT.

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
接受健康志愿者

入选标准

  • Willing and mentally legally capable to provide written informed consent
  • 18 years of age or older
  • One of the following clinical scenario’s: • New diagnosis of HCC, confirmed either by biopsy or imaging using EASL/AASLD criteria, with a high risk of metastases indicated by portal invasion or a primary lesion of >5cm diameter. • Known diagnosis of HCC that requires restaging due to unexplained elevated AFP tumor markers, known metastases, impending initiation of immunotherapy, or being on the waiting list for a liver transplant.
  • Have either planned or recently undergone (within the past 4 weeks) both F-18 FDG PET/CT and F-18 Choline PET/CT scans as part of their diagnostic or staging workup for one of the above indications.

排除标准

  • Known active malignancy other than hepatocellular carcinoma.
  • History of prostate cancer
  • Active pregnancy
  • Possible pregnancy and refusal of urine pregnancy test

结局指标

主要结局

Per-lesion detection rate of F-18 PSMA-11 PET/CT, 60-90 minutes post-injection.

Per-lesion detection rate of F-18 PSMA-11 PET/CT, 60-90 minutes post-injection.

次要结局

  • Overall Survival (OS) and Progression-Free Survival (PFS): Measured among subjects with PSMA-avid, FDG-avid, and Choline-avid HCC lesions, measured after completion of the 2 year follow-up for all patients.
  • Tumor-to-Background Ratio: Assessed for intrahepatic HCC lesions 60-90 minutes post-injection using F-18 PSMA-11 PET/CT.
  • Standard Uptake Value (SUV) Parameters: Analyzed for all HCC lesions detected 60-90 minutes post-injection with F-18 PSMA-11 PET/CT.
  • Proportion of subjects with Metastatic HCC: Comparison between those detected by F-18 PSMA-11 PET/CT, F-18 FDG PET, and F-18 Choline PET, 60-90 minutes post-injection.

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Robbe Waterschoot

Scientific

Universitair Ziekenhuis Gent

研究点 (1)

Loading locations...

相似试验